Aspire Biopharma Holdings, Inc.
Aspire Biopharma Holdings, Inc. (ASBP) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
asbp · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Aspire Biopharma Holdings, Inc. (ASBP) measures how much investors pay for each dollar of the company's trailing earnings. ASBP's current PE ratio of N/A is calculated by dividing its stock price of $6.65 by its TTM earnings per share of -$7.87.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2021 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Aspire Biopharma Holdings, Inc.You ASBP | $1M | N/A | — | -$7.87 |
 AleAnna, Inc. ANNA | $125M | 65.04x | -44.0% | $0.04 |
 Blue Ocean Acquisition Corp. BOCN | $71M | 47.81x | -58.8% | $0.23 |
 Collective Audience, Inc. CAUD | $0M | N/A | — | -$0.33 |
 Catcha Investment Corp CHAA | $78M | N/A | — | -$0.47 |
 Consilium Acquisition Corp I, Ltd. CSLM | $72M | 235.45x | +102.8% | $0.05 |
 Focus Impact Acquisition Corp. FIAC | $66M | N/A | — | $0.00 |
Industry Average 3 peers with valid PE | — | 116.10x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-16.38 | — | |
2024-12-31 FY2024 | — | $-18.17 | — | |
2023-12-31 FY2023 | 1403.63x | $9.31 | -57.8% | |
2022-12-31 FY2022 | 3324.75x | $3.72 | — | |
2021-12-31 FY2021 | — | $-0.04 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Aspire Biopharma Holdings, Inc. (ASBP) measures how much investors pay for each dollar of the company's trailing earnings. ASBP's current PE ratio of N/A is calculated by dividing its stock price of $6.65 by its TTM earnings per share of -$7.87.
Frequently asked questions
ASBP pe ratio · 6 questionsASBP's current PE ratio is N/A as of 2026-06-09, based on a stock price of $6.65 and TTM EPS of -$7.87. Data sourced from Financial Modeling Prep via ASBP's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Aspire Biopharma Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09